Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Viking Therapeutics, Inc.NASDAQ: VKTX
Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026
Change in working capital turns negative
Q2 FY2026 change in working capital was -$7.64M, compared with $7.2M a year earlier. Trailing-twelve-month change in working capital was $84.42M. Over 3 fiscal years it compounded at +68.8% a year.
Context
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly change in working capital holds near -$7.64M or moves back toward the trailing-twelve-month quarterly average of $21.1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 48.98M USD
- Year-over-year change
- +423.2%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.98M | +423.2% |
| FY2024 | 2024-12-31 | 9.36M | +163.9% |
| FY2023 | 2023-12-31 | 3.55M | -65.2% |
| FY2022 | 2022-12-31 | 10.19M | +448.1% |
| FY2021 | 2021-12-31 | (2.93M) | — |
Change in Working Capital vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 change in working capital of $84.42M is the largest of the 7 companies compared; the peer median is $3.62M.
- Its year-over-year change of +1412.1% is the 2nd highest of 6, against a peer median of -34.8%.
- Over three fiscal years its annual growth of +68.8% compares with a peer median of +6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $84.42M | +1412.1% | +68.8% | — | |
| LTM Jun 2026 | $72.34M | -34.8% | — | 5.6% | |
| LTM Mar 2026 | $18.69M | +942.0% | -29.4% | 50.7% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $16.78M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $11.65M | +1978.7% | +6.9% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $6.99M | -104.2% | +353.4% | 7.3% |
| LTM Jun 2026 | $247K | -98.8% | — | 3.5% | |
| Peer median (excluding VKTX) | $3.62M | -34.8% | +6.9% | 6.4% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 8.67M | 16.75M | 29.71M | 40.82M |
| Change in Working Capital | (2.93M) | 10.19M | 3.55M | 9.36M | 48.98M |
| Accounts Receivables | 1.18M | 614K | 321K | 1.2M | 5.08M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.54M) | 7.09M | (1.02M) | 2.3M | 43.44M |
| Other Working Capital | (1.56M) | 2.49M | 4.25M | 5.86M | 464K |
| Other Non-Cash Items | 3.94M | 1.32M | (8.07M) | (17.25M) | (9.27M) |
| Operating Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (168.02M) | (121.43M) | (478.3M) | (1.11B) | (418.04M) |
| Sales of Investments | 205.98M | 176.18M | 299.22M | 560M | 759.43M |
| Other Investing Activities | 0 | 54.75K | 0 | 0 | 0 |
| Investing Cash Flow | 37.96M | 54.75M | (179.09M) | (553.37M) | 341.39M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 7.59M | 0 | 269.76M | 597.09M | 2.49M |
| Common Stock Repurchased | 0 | (6.8M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (707K) | 12.49M | 1.62M | 15.37M | 73.95M |
| Financing Cash Flow | 6.88M | 4.16M | 271.38M | 612.46M | 76.44M |
| Effect of Forex Changes | 0 | (258K) | (30K) | (148K) | (8K) |
| Net Change in Cash | (2.75M) | 10.26M | 18.88M | (28.84M) | 139.13M |
| Free Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.